| Registry | NCT01068795 |
|---|---|
| Status | Completed |
| Phase | Not applicable |
| Study type | Interventional; randomized, parallel, masking: none, prevention |
| Enrollment | 144 (Actual) |
| Sponsor | HaEmek Medical Center, Israel (Other) |
| Conditions | Fetal Demise, Fetal Growth Restriction, Preeclampsia, Abruptio Placentae, Thromboembolism |
| Interventions | enoxaparin (Drug) |
| Dates | start 2009-07-01, primary completion 2015-01-01, completion 2015-08-01, first posted 2010-02-15, last updated 2016-02-23 |
| Locations | 1 site in Israel |
Related Papers Related Patents Related Grants Related Experts
All trials for Fetal Demise All trials for Fetal Growth Restriction All trials of enoxaparin
The risk of venous thromboembolism increases in pregnancy. Thrombophilia whether genetic or acquired, is a hypercoagulable disorder that may increase the risk of venous thromboembolic events. Clinically, these events are presented as maternal deep vein thrombosis and pulmonary emboli. Thrombophilias are also associated with adverse fetal outcomes including intrauterine growth restriction, intrauterine fetal death, severe preeclampsia, placental abruption and recurrent abortions.
Pregnant women who experienced one or more of the above complications are advised to be examined for the presence of the genetic or the acquired form of thrombophilia.
Low molecular weight heparin prophylaxis, an anticoagulant, is advised for pregnant women with a history of thromboembolism, and many experts recommend prophylaxis for pregnant patients with a known thrombophilia and history of adverse pregnancy outcomes associated with these hypercoagulable states.
Physiologic changes in normal pregnancy, including weight gain, increased renal clearance and volume of distribution, may decrease the availability of low molecular weight heparin (Enoxaparin or Dalteparin), or produce a less predictable response in pregnant women compared with nonpregnant women. There are no clear recommendations for use of prophylactic low molecular weight heparin in pregnancy. Clinicians tend to use doses suggested for nonpregnant patients. Regarding pregnant patients taking enoxaparin or dalteparin, the American College of Obstetricians and Gynecologists states that "because of the lack of data regarding adequate dosing during pregnancy, anti-factor Xa levels may be monitored".
Two recently published studies demonstrated that plasma anti-factor Xa levels during pregnancy were lower than expected, indicating that many pregnant patients may receive a subprophylactic dosing.
Our objective is to check pregnancy outcome among thrombophilic women treated with an adjusted enoxaparin thromboprophylaxis dosage according to anti-factor Xa plasma levels compared to women with fixed dosage.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| enoxaparin fixed | No intervention | enoxaparin dosage will be fixed during pregnancy | |
| enoxaparin adjusted | Experimental | Drug: enoxaparin | enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels |
Sex: Female, ages: 18 Years to 45 Years
Inclusion Criteria: WOMEN WITH * Singleton gestation * A history of fetal demise, fetal growth restriction, placental abruption, preeclampsia, recurrent abortions or maternal thromboembolic event. * Acquired or congenital thrombophilia treated with low molecular weight heparin Exclusion Criteria: * Women treated empirically with low molecular weight heparin * Women with a history of pregestational diabetes. * Significant polyhydramnios or oligohydramnios, major fetal structural, generic or chromosomal malformations
| Facility | City | Country | Status |
|---|---|---|---|
| Dep. OB/GYN, HaEmek Medical Center | Afula | Israel |